AbbVie

ABBVNYSE

Commercial biopharma portfolio spanning antibodies, small molecules, and aesthetics

Drafted with AI assistance from public sources and not individually reviewed by an editor; last updated 2026-04-09. Published by ClinicalInvestor. Educational analysis only. Read the editorial policy and disclosures.

text updated 2026-04-09, 222 days ago · archived: kept for reference, not maintained · where each field comes from

Key figures from SEC filings

We have not parsed a 10-Q or 10-K for ABBV yet, so this page shows no cash, burn or runway figure rather than an estimate. Revenue stage: Commercial.

Upcoming catalysts

Company-specific dates below are registry milestones or filings we have linked. For FDA decision dates site-wide, see the PDUFA calendar.

Venetoclax ramp-up CLL: Venetoclax in Previously untreated chronic lymphocytic leukaemia — primary completion

2028-03

Registry milestone — the date data collection is scheduled to end, not when results are released. ClinicalTrials.gov

Trial milestoneSignificant

Pipeline

DrugIndicationPhaseExpected data
Skyrizipsoriasis, inflammatory bowel disease, and related immunology usesApprovedNot disclosed▼
Rinvoqmultiple inflammatory diseasesApprovedNot disclosed▼
Telisotuzumab vedotinc-Met overexpressing non-small cell lung cancerPhase 3Not disclosed▼

Analysis

We have not yet written an analysis of AbbVie that is specific and current enough to publish. Earlier text here was removed rather than left up: on most profiles it was a template shared with other companies, and where a correction is listed above, it was written before the facts changed. The filing figures, pipeline and sourced catalysts on this page are current; the written thesis will be added from them.
Trade ABBV commission-free on Webullvia Webull · Affiliate

Comparable companies

AmgenGilead SciencesBristol Myers Squibb

Sponsored

Get premium ABBV analysis on Seeking Alpha

Affiliate link — we may earn a commission at no cost to you

Disclaimer: This page is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell securities. Clinical trial analysis reflects publicly available data and AI-generated interpretations. Biotech investing carries significant risk including potential total loss of investment. Always verify critical claims through primary sources and consult a qualified financial advisor. Some links on this page are affiliate links. Review our editorial policy and disclosures.

Sponsor's late-stage trial record

AbbVie has 571 Phase 2 or 3 studies on ClinicalTrials.gov: 389 completed, 53 stopped early, 129 ongoing.

389

Completed

53

Stopped early

129

Ongoing

Stopped early

  • NCT05316220Phase 3 · started 2025 · withdrawn

    Mesalamine in ulcerative colitis (uc) · n=0

    Reason given: strategic considerations

  • NCT06093503Phase 3 · started 2024 · withdrawn

    Telisotuzumab Vedotin in non-small cell lung cancer · n=0

    Reason given: Strategic considerations

  • Sleep UpPhase 3 · started 2024 · withdrawn

    Upadacitinib in atopic dermatitis · n=0

    Reason given: strategic decision

  • NCT05606757Phase 2 · started 2024 · withdrawn

    BOTOX Dose A in ventral hernia · n=0

    Reason given: Strategic considerations

  • NCT06032546Phase 2 · started 2023 · terminated

    Budigalimab in human immuno-deficiency virus (hiv) disease · n=163

    Reason given: Company Decision

  • NCT05941442Phase 2 · started 2023 · terminated

    Darigabat in panic disorder · n=80

    Reason given: Sponsor terminated due to significant enrollment and study design challenges

  • NCT05785715Phase 2 · started 2023 · terminated

    NX-13 250mg in ulcerative colitis · n=81

    Reason given: Sponsor Decision\_Not Safety Related

  • NCT05513703Phase 2 · started 2022 · terminated

    Telisotuzumab Vedotin in non small cell lung cancer · n=9

    Reason given: Strategic considerations

  • NCT05443724Phase 2 · started 2022 · terminated

    Emraclidine 30 mg in schizophrenia · n=698

    Reason given: The study was terminated due to business reasons, not safety reasons.

  • 509 JPN SchzPhase 3 · started 2022 · terminated

    Cariprazine in schizophrenia · n=34

    Reason given: Strategic considerations

  • AIM-CDPhase 2 · started 2022 · terminated

    ABBV-154 in crohn's disease · n=176

    Reason given: Strategic considerations

  • NCT05044234Phase 2 · started 2021 · terminated

    Cedirogant in psoriasis · n=156

    Reason given: Company Decision

  • NCT05028569Phase 3 · started 2021 · terminated

    BOTOX in episodic migraine · n=775

    Reason given: The study was terminated early due to lack of efficacy from the primary analysis results.

  • NCT04853368Phase 2 · started 2021 · terminated

    ABBV-576 in cystic fibrosis (cf) · n=48

    Reason given: Strategic considerations

  • AIM-PMRPhase 2 · started 2021 · terminated

    ABBV-154 in polymyalgia rheumatica · n=181

    Reason given: Strategic considerations

  • CAR aGAD Ph 2Phase 2 · started 2021 · withdrawn

    Cariprazine 0.75 mg/day in generalized anxiety disorder · n=0

    Reason given: Strategic Decision

  • NCT04888585Phase 2 · started 2021 · terminated

    ABBV-154 in rheumatoid arthritis (ra) · n=473

    Reason given: Business decision

  • NCT04958031Phase 2 · started 2021 · terminated

    CVL-871 1.0 mg in apathy in dementia · n=41

    Reason given: Sponsor Decision - Not Safety Related

  • NCT04913610Phase 2 · started 2021 · terminated

    ABBV-4083 in onchocerciasis · n=153

    Reason given: Strategic considerations

  • NCT04666675Phase 3 · started 2020 · withdrawn

    Upadacitinib in atopic dermatitis (ad) · n=0

    Reason given: Strategic considerations

  • NCT04686786Phase 2 · started 2020 · terminated

    CVL-865 in seizures · n=105

    Reason given: Closed early after CVL-865-SZ-001 (NCT04244175) did not meet its primary objective

  • NCT04064827Phase 3 · started 2020 · terminated

    Paricalcitol in chronic kidney disease (ckd) · n=2

    Reason given: Company Decision

  • NCT04403763Phase 1/2 · started 2020 · terminated

    AGN-241622 in presbyopia · n=80

    Reason given: Strategic considerations

  • NCT05217472Phase 2 · started 2020 · withdrawn

    Ravaglimab in sjogren's syndrome (ss) · n=0

    Reason given: Study canceled

  • VIALE-TPhase 3 · started 2020 · terminated

    Venetoclax in acute myeloid leukemia (aml) · n=465

    Reason given: Strategic considerations

  • NCT03823378Phase 2 · started 2019 · terminated

    Elsubrutinib in rheumatoid arthritis (ra) · n=97

    Reason given: Study M16-763 was terminated early as the benefit of each treatment arm from the feeder study (Study M16-063) did not provide appreciable evidence of differentiated clinical effect to warrant further long-term continuation.

  • NCT03785184Phase 2 · started 2019 · withdrawn

    venetoclax in multiple myeloma · n=0

    Reason given: Strategic considerations

  • NCT03712787Phase 2 · started 2019 · terminated

    Tilavonemab in alzheimer's disease · n=364

    Reason given: Discontinued because of lack of efficacy in the parent study (Study M15-566; NCT02880956).

  • NCT03567616Phase 2 · started 2018 · terminated

    Venetoclax in multiple myeloma · n=8

    Reason given: Following results of the primary progression-free survival analysis from Study NCT02755597, company-sponsored MM studies were placed on partial clinical hold (PCH). Sponsor did not pursue release of the PCH for this study.

  • NCT03593213Phase 3 · started 2018 · terminated

    Cariprazine in schizophrenia · n=587

    Reason given: FDA Released Allergan from this post marketing requirement

  • NCT03419403Phase 3 · started 2018 · terminated

    Steroid eye drops in glioblastoma multiforme · n=40

    Reason given: The study was terminated because clinical development of depatuxizumab mafodotin in glioblastoma was stopped due to lack of survival benefit.

  • NCT03368859Phase 2 · started 2018 · terminated

    Leucovorin in cancer · n=70

    Reason given: Study may continue

  • NCT03334487Phase 3 · started 2018 · withdrawn

    Dexamethasone in small cell lung cancer · n=0

    Reason given: Strategic considerations

  • NCT03391765Phase 2 · started 2018 · terminated

    ABBV-8E12 in progressive supranuclear palsy (psp) · n=142

    Reason given: This study was prematurely discontinued because the program for progressive supranuclear palsy was discontinued due to lack of efficacy.

  • NCT03343067Phase 3 · started 2017 · terminated

    elagolix in endometriosis · n=11

    Reason given: The study was terminated early for business reasons, not for safety concerns.

  • NCT03148756Phase 2 · started 2017 · terminated

    Dalbavancin in endocarditis · n=2

    Reason given: Study stopped due to business reasons.

  • NCT03026166Phase 1/2 · started 2017 · terminated

    Ipilimumab in small cell lung cancer · n=42

    Reason given: Enrollment was stopped after the dose-limiting toxicity (DLT) evaluation phase of Cohort 2.

  • MERUPhase 3 · started 2017 · terminated

    Placebo for dexamethasone in small cell lung cancer · n=748

    Reason given: Independent Data Monitoring Committee recommendation

  • NCT02985879Phase 2 · started 2016 · terminated

    Placebo in progressive supranuclear palsy · n=378

    Reason given: This study was prematurely discontinued because the program for progressive supranuclear palsy was discontinued due to lack of efficacy of study drug.

  • NCT02709889Phase 1/2 · started 2016 · terminated

    Rovalpituzumab tesirine in malignant melanoma · n=200

    Reason given: Strategic considerations

  • GIFT-RPhase 3 · started 2016 · withdrawn

    Ombitasvir/paritaprevir/ritonavir in chronic hepatitis c virus · n=0

    Reason given: Study halted prematurely, prior to enrollment of first participant

  • NCT02429895Phase 2 · started 2015 · terminated

    ABT-122 in psoriatic arthritis · n=168

    Reason given: Internal business decision

  • VELIAPhase 3 · started 2015 · terminated

    Veliparib in ovarian cancer · n=1140

    Reason given: Business decision not related to patient safety

  • GEODE - IPhase 3 · started 2015 · terminated

    ombitasvir/paritaprevir/ritonavir and dasabuvir in chronic hepatitis c infection · n=3

    Reason given: Study stopped due to low enrollment

  • NCT02412371Phase 1/2 · started 2015 · terminated

    Paclitaxel in non-small cell lung cancer stage iii · n=48

    Reason given: Phase 2 was not conducted due to a change in the standard of care for newly diagnosed, unresectable Stage III NSCLC

  • NCT02082197Phase 3 · started 2014 · withdrawn

    ABT-SLV176 in hypogonadism · n=0

    Reason given: Other - not a safety issue

  • SONARPhase 3 · started 2013 · terminated

    Atrasentan in diabetic nephropathy · n=5107

    Reason given: Strategic considerations

  • NCT01897519Phase 2 · started 2013 · terminated

    Placebo in cardiothoracic surgery · n=56

    Reason given: Topline results from study M13-796 showed an overall lack of efficacy. There were no safety concerns.

  • NCT01834638Phase 2 · started 2013 · terminated

    ABT-126 in schizophrenia · n=268

    Reason given: Study endpoint in preceding base study M10-855 not met.

  • NCT01690195Phase 2 · started 2012 · terminated

    ABT-126 in alzheimer's disease · n=343

    Reason given: Data obtained from the M11-428 study is not critical to the continued evaluation of ABT-126.

  • NCT01676935Phase 2 · started 2012 · terminated

    ABT-126 in alzheimer's disease · n=349

    Reason given: Data obtained from the M11-427 study is not critical to the continued evaluation of ABT-126.

  • NCT01579279Phase 2 · started 2012 · terminated

    ABT-652 6 mg in diabetic neuropathic pain · n=1

    Reason given: Study Stopped

  • NCT01741142Phase 2 · started 2012 · terminated

    ABT-436 in major depressive disorder · n=19

    Reason given: Decision based on strategic determination; not safety.

Counts cover interventional Phase 2 and Phase 3 studies registered under this sponsor name, retrieved 2026-09-28 from ClinicalTrials.gov API v2. Trials stop for many reasons — futility, safety, enrollment, funding, or a decision to back a different programme — and the registry often does not say which. This is the sponsor's record, not a prediction about any specific readout.